tradmap

TARS Tarsus Pharmaceuticals, Inc.

$83.12 +0.41%

Updated

Healthcare · Biological Products, (No Diagnostic Substances)

Tarsus Pharmaceuticals, Inc. (TARS) is a healthcare company in the Biological Products, (No Diagnostic Substances) industry, with a market capitalization of $3.6 billion. Shares last traded at $83.12, near their 52-week high. Over the past year the stock is up 44.1%. Net profit margin is -7.7%, below the peer median of 5.3%. Revenue grew 146.7% year over year.

Market Cap
$3.6B
Shares Out
43.9M
EPS (TTM)
$-3.26
P/E Ratio
P/S Ratio
6.02
P/B Ratio
10.52
Dividend / Share
Dividend Yield
52-Week High
$85.25
52-Week Low
$48.26
Volume
42,807
Avg Vol (3m)
68,470.175

Performance

1W
+15.52%
1M
+35.78%
3M
+37.66%
6M
+11.00%
YTD
+3.13%
1Y
+44.08%

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)
78.90
SMA (50)
$65.41
SMA (200)
$68.68
Price vs SMA50
+27.07%
Price vs SMA200
+21.03%
ATR (14)
$4.19

Full technical analysis (26 indicators, D/W/M) →

Financials

Revenue
$606M
Net Income
$-46M
Gross Margin
Operating Margin
-8.0%
Net Margin
-7.7%
Return on Equity
-13.4%
Return on Assets
-7.6%
Current Ratio
3.20
Debt / Equity
0.21
Revenue Growth (YoY)
+146.7%

Latest reported annual period ending 2026-06-30 · SEC EDGAR/XBRL.

Full financials — revenue, cash flow & debt over time →

Recent earnings

PeriodEPS (diluted)Reported
Q2 2026 $-0.59 2026-08-06
Q1 2026 $-0.16 2026-05-06
FY 2025 $-1.59 2026-02-23
Q3 2025 $-1.40 2025-11-04
Q2 2026 $-1.11 2026-08-06
Q1 2026 $-0.64 2026-05-06

Full earnings history →

Biological Products, (No Diagnostic Substances) peers

TARS vs 14 industry peers (Biological Products, (No Diagnostic Substances)), by market cap. Updated

P/S vs peers
6.02 / 19.49 med
-69% discount
Net margin vs peers
-7.7% / 5.3% med
below median
1–14 of 14
AMGNAmgen$240.1B27.476.3023.0%+0.31%
GILDGilead Sciences$187.5B-57.876.16-10.6%+1.09%
MRNAModerna$58.8B-18.68-1.94%
RVMDRevolution Medicines, Inc.$45.2B-25.55+0.76%
BIIBBiogen$33.1B24.163.3413.8%+0.78%
NBIXNeurocrine Biosciences Inc$16.1B22.814.7720.9%+0.33%
EXELExelixis, Inc.$14.7B17.036.0235.3%+1.00%
HALOHalozyme Therapeutics, Inc.$12.6B30.397.5524.9%+1.01%
TECHBio-Techne$11.4B62.489.3515.0%+0.21%
KRYSKrystal Biotech, Inc.$11.0B45.5224.9554.8%+0.58%
APGEApogee Therapeutics, Inc.$10.2B-34.57+0.04%
KYMRKymera Therapeutics, Inc.$9.7B-32.51-1.24%
RGENRepligen Corp$9.6B230.5312.205.3%-1.87%
PCVXVaxcyte, Inc.$9.1B-8.56-0.62%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.